Parkinson's disease 'may' start in gut

Maricruz Casares
Noviembre 4, 2018

On the other hand, timely removal of appendicitis delays the diagnosis of Parkinson's in patients by 3.6 years on average. During their study, researchers focused on identifying the factors influencing the development of the disease that focus outside of the human brain.

In Parkinson's disease, toxic proteins accumulate in the brain and kill nerves, especially those linked to movement.

The function of the appendix for a long time has not been explained but recently have been discovered to contain a substance that destroys the brain cells.

The scientists also found an interesting fact, the essence of which lies in the relationship between the operation to remove the Appendix and development of Parkinson's.

More news: Renueva el IFT por 20 años las concesiones de Televisa

The tiny appendix may be a hidden source of risk for the onset of Parkinson's disease and its removal reduces by 25% the risk of this incurable neurological disorder, according to a new global scientific research, the largest of its kind to date. The researchers analyzed medical cards of one million seven hundred thousand people.

Research suggests that severing this nerve may prevent sticky clumps of a protein called alpha-synuclein, from spreading to the brain, reducing the Parkinson's risk.

The same abnormally folded proteins are also found in people that are not diagnosed with the neurodegenerative disease. For those living in rural areas it was even more advantageous, as there was a 25-percent reduction in disease risk, the reveals. Given the appendix's potential role in maintaining the gut microbiome as well as in the immune system, perhaps there's actually some link between fluctuations in the microbiome or inflammation and Parkinson's as well, said Labrie. "The findings suggest that the appendix might be important in the early events or possibly in the initiation of this disease", said Labrie.

But this is a potential avenue for treatment, and drug companies are interested in targeting the protein in people who already have Parkinson's, Patrik Brundin, director of the Centre for Neurodegenerative Science at the Van Andel Research Institute, said in the teleconference.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO